Press Releases August 6, 2026 06:00 AM

Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results

Privia Health Reports Strong Q2 and Year-to-Date 2026 Results, Raises Full-Year Guidance

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
PRVA

Privia Health Group, Inc. announced robust financial results for Q2 and the first six months of 2026, showing significant growth in net income, adjusted EBITDA, and practice collections compared to the previous year. The company raised its full-year 2026 guidance across all key financial metrics, indicating confidence in ongoing growth and profitability.

Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
PRVA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Second quarter net income increased by 236.7% to $9.0 million compared to Q2 2025.
  • Adjusted EBITDA rose by 29.1% in Q2 2026, reaching $37.4 million, highlighting improved operational efficiency.
  • Full-year 2026 guidance was raised for implemented providers, attributed lives, practice collections, revenue, care margin, platform contribution, and adjusted EBITDA, reflecting strong business momentum.
  • The healthcare sector, especially physician enablement and value-based care models, is positively impacted by Privia Health’s growth and technology platform expansion.
  • 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25
  • 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25
  • Full-Year 2026 Guidance Raised for All Key Financial Metrics

ARLINGTON, Va., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the second quarter and six-month periods ended June 30, 2026.

Second Quarter Performance

  Three Months Ended June 30,  (unaudited; $ in millions, except per share amounts)  2026  2025 Change (%)*Total revenue $632.6 $521.2 21.4%Gross profit $128.9 $112.8 14.3%Operating income $11.8 $3.3 252.9%Net incomea $9.0 $2.7 236.7%Non-GAAP adjusted net incomeb $25.3 $21.3 18.7%Net income per share $0.07 $0.02 250.0%Non-GAAP adjusted net income per shareb $0.19 $0.17 11.8%            *Any slight variations in totals are due to rounding.
  1. Net income for the three months ended June 30, 2026, included $19.4 million in non-cash stock compensation expense. Net income for the three months ended June 30, 2025 included $18.8 million in non-cash stock compensation expense.
  2. Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release.

Key Operating and Non-GAAP Financial Metrics c

  Three Months Ended June 30,  (unaudited; $ in millions)  2026  2025 Change (%)       Implemented Providers  5,644  5,125 10.1%Value-Based Care Attributed Lives  1,647,000  1,382,000 19.2%Practice Collections $970.0 $862.9 12.4%Care Margin $132.1 $115.2 14.7%Platform Contribution $69.0 $57.5 20.1%Adjusted EBITDA $37.4 $29.0 29.1%       c. Reconciliations of Care Margin, Platform Contribution, Adjusted EBITDA and other non-GAAP financial measures are presented in tables near the end of this press release.

Six-Month Performance

  For the Six Months Ended June 30,  ($ in millions, except per share amounts)  2026  2025 Change (%)       Total revenue $1,236.5 $1,001.3 23.5%Gross profit $254.5 $216.4 17.6%Operating income $19.2 $8.6 124.4%Net incomea $12.1 $6.9 75.4%Non-GAAP adjusted net incomeb d e $49.6 $41.2 20.4%Net income per share $0.09 $0.05 80.0%Non-GAAP adjusted net income per shareb d e $0.38 $0.32 18.8%       
  1. Net income for the six months ended June 30, 2026 included $41.3 million in non-cash stock compensation expense. Net income for the six months ended June 30, 2025 included $36.6 million in non-cash stock compensation expense.
  2. Reconciliations of non-GAAP adjusted net income and other non-GAAP financial measures are presented in tables near the end of this press release.

Key Operating and Non-GAAP Financial Metrics b d e

  For the Six Months Ended June 30,  ($ in millions)  2026  2025 Change (%)       Practice Collections $1,884.8 $1,661.5 13.4%Care Marginb d $260.9 $220.4 18.3%Platform Contributionb d $136.0 $109.2 24.6%Adjusted EBITDAb d e $74.1 $55.9 32.6%       

Updated Full-Year 2026 Guidance d e f g

 FY 2025 Initial FY 2026 Guidance at 2.27.26d Updated FY 2026 Guidance at 8.6.26($ in millions)Actual Low High  Implemented Providers 5,380  5,900  6,000 No ChangeAttributed Lives 1,541,000  1,550,000  1,600,000 1,625,000 - 1,650,000Practice Collections$3,470.5 $3,650 $3,750 High EndGAAP Revenue$2,122.8 $2,350 $2,450 High EndCare Margind e f$462.2 $515 $530 Mid to High EndPlatform Contributiond e$234.8 $260 $270 Mid to High EndAdjusted EBITDAd e f$125.5 $145 $155 Mid to High End
  • Expect approximately 70-80% of Adjusted EBITDA to convert to free cash flow in full-year 2026 subject to timing of MSSP cash settlement
  • Guidance does not assume any new business development activity

d. Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of Gross Profit, Operating Income and Net Income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.

e. See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.

f. Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly press releases.

g. Any slight variations in totals due to rounding.

Webcast and Conference Call Information

The Company will host a conference call on August 6, 2026, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. Go to https://register-conf.media-server.com/register/BI4c0355cb60f4473db6a27e261c9996e2 in order to pre-register and obtain your dial-in number and passcode to join the live conference call.

This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.

About Privia Health

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 6.1+ million patients, and reward 5,600+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

Non-GAAP Financial Measures

The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.

The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.

Safe Harbor Statement

The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things, our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full year guidance for 2026. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.

Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the execution of our growth strategy, which may not prove viable and we may not realize expected results; difficulties timely implementing our proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in our industry; challenges in successfully establishing a presence in new geographic markets; the impact of failures by or service disruptions at key third-party vendors, such as our primary electronic medical record vendor, athenahealth, Inc.; potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting our patient population; the financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential security threats, cybersecurity incidents or privacy or other forms of data breaches involving us, our vendors or other third parties; the continued availability of qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Contact:Robert BorchertSVP, Investor & Corporate [email protected]

 Privia Health Group, Inc.
Condensed Consolidated Statements of Operations(g)
(unaudited)
(in thousands, except share and per share data)

     For the Three Months Ended June 30, For the Six Months Ended June 30,  2026  2025  2026  2025        Revenue$632,630 $521,153 $1,236,477 $1,001,250        Operating expenses:       Provider expense 500,484  405,992  975,601  780,801Cost of platform 69,357  64,918  137,777  124,444Sales and marketing 8,002  6,805  16,136  13,727General and administrative 39,658  37,519  81,131  69,240Depreciation and amortization 3,356  2,583  6,637  4,484Total operating expenses 620,857  517,817  1,217,282  992,696Operating income 11,773  3,336  19,195  8,554Other income 3,310  —  3,310  —Interest income, net 1,668  2,408  3,556  5,339Income before provision for income taxes 16,751  5,744  26,061  13,893Provision for income taxes 7,017  2,456  12,617  4,559Net income 9,734  3,288  13,444  9,334Less: Net income attributable to non-controlling interests 686  601  1,332  2,427Net income attributable to Privia Health Group, Inc.$9,048 $2,687 $12,112 $6,907Net income per share attributable to Privia Health Group, Inc. stockholders – basic$0.07 $0.02 $0.10 $0.06Net income per share attributable to Privia Health Group, Inc. stockholders – diluted$0.07 $0.02 $0.09 $0.05Weighted average common shares outstanding – basic 126,121,426  122,132,245  125,142,415  121,370,949Weighted average common shares outstanding – diluted 131,827,233  128,447,069  131,355,421  128,149,252

(g) Any slight variations in totals due to rounding.

 Privia Health Group, Inc.
Condensed Consolidated Balance Sheets(h)
(in thousands)

     June 30, 2026 December 31, 2025Assets(unaudited)  Current assets:   Cash and cash equivalents$412,200  $479,685 Accounts receivable 574,160   400,902 Prepaid expenses and other current assets 38,906   30,414 Total current assets 1,025,266   911,001 Non-current assets:   Property and equipment, net 272   504 Right-of-use assets 8,038   8,794 Intangible assets, net 218,654   215,919 Goodwill 215,789   209,842 Deferred tax asset —   2,274 Other non-current assets 20,562   21,044 Total non-current assets 463,315   458,377 Total assets$1,488,581  $1,369,378     Liabilities and stockholders’ equity   Current liabilities:   Accounts payable and accrued expenses$91,010  $96,804 Provider liability 541,368   469,516 Operating lease liabilities, current 2,066   2,200 Total current liabilities 634,444   568,520 Non-current liabilities:   Operating lease liabilities, non-current 6,667   7,331 Deferred tax liability 3,737   — Other non-current liabilities 5,660   2,584 Total non-current liabilities 16,064   9,915 Total liabilities 650,508   578,435 Commitments and contingencies   Stockholders’ equity:   Common stock 1,263   1,236 Additional paid-in capital 925,264   892,291 Accumulated deficit (144,198)  (156,310)Total Privia Health Group, Inc. stockholders’ equity 782,329   737,217 Non-controlling interest 55,744   53,726 Total stockholders’ equity 838,073   790,943 Total liabilities and stockholders’ equity$1,488,581  $1,369,378 

(h) Any slight variations in totals are due to rounding.

 Privia Health Group, Inc.
Condensed ConsolidatedStatementsof Cash Flows(i)
(unaudited)
(in thousands)   For the Six Months Ended June 30,  2026   2025 Cash flows from operating activities   Net income$13,444  $9,334 Adjustments to reconcile net income to net cash used in operating activities:   Depreciation 291   415 Amortization of intangibles 6,346   4,069 Stock-based compensation 41,317   36,639 Deferred income taxes, net 3,683   2,671 Changes in asset and liabilities:   Accounts receivable, net (172,378)  (121,497)Prepaid expenses and other current assets (8,492)  (21,344)Other non-current assets and right-of-use assets 1,472   1,056 Accounts payable and accrued expenses (5,794)  (7,687)Provider liability 70,972   81,185 Operating lease liabilities (1,032)  (778)Other long-term liabilities 1,806   (153)Net cash used in operating activities (48,365)  (16,090)Cash from investing activities   Business acquisitions, net of cash acquired (11,430)  (89,058)Other (59)  — Net cash used in investing activities (11,489)  (89,058)Cash flows from financing activities   Proceeds from exercised stock options 1,600   4,126 Proceeds from non-controlling interest 2,213   — Repurchase of non-controlling interest (11,444)  — Net cash (used in) provided by financing activities (7,631)  4,126 Net decrease in cash and cash equivalents (67,485)  (101,022)Cash and cash equivalents at beginning of period 479,685   491,149 Cash and cash equivalents at end of period$412,200  $390,127     Supplemental disclosure of cash flow information:   Interest paid$162  $124 Income taxes paid$10,656  $5,771     Supplemental disclosure of non-cash operating activities:   Lease liabilities obtained in exchange for right-of-use assets$234  $1,832 Contingent consideration payable$1,270  $— 

(i) Any slight variations in totals are due to rounding.

Additional Financial Information

Revenues disaggregated by source:

 For the Three Months Ended June 30, For the Six Months Ended June 30,(Dollars in thousands) 2026  2025  2026  2025FFS-patient care$412,640 $331,464 $803,773 $643,225FFS-administrative services 33,222  35,116  64,625  67,371Capitated revenue 95,150  75,511  181,298  146,201Shared savings 68,920  60,021  143,883  107,933Care management fees (PMPM) 20,733  16,919  38,600  32,121Other revenue 1,965  2,122  4,298  4,399Total Revenue$632,630 $521,153 $1,236,477 $1,001,250

The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:

  June 30,(Dollars in thousands)  2026   2025 Balance, beginning of period $78,989  $66,355 Incurred health care costs:    Current year  175,800   144,840 Prior years  (13,225)  (555)Total claims incurred $162,575  $144,285 Claims paid:    Current year  (83,892)  (63,025)Prior year  (58,695)  (47,959)Total claims paid $(142,587) $(110,984)Balance, end of period $98,977  $99,656 

Key Metrics and Non-GAAP Financial Measures

Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.

Key Metrics(j)

  For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in millions)  2026  2025  2026  2025         Implemented Providers (as of end of period)(1)  5,644  5,125  5,644  5,125Attributed Lives (as of end of period)(2)  1,647,000  1,382,000  1,647,000  1,382,000Practice Collections(3) $970.0 $862.9 $1,884.8 $1,661.5         (1)Implemented Providers is defined as the total of all service professionals at the end of a given period who are credentialed and bill for medical services in both Owned and Non-Owned Medical Groups during that period.(2)Attributed Lives are defined as any patient that a payer deems attributed to Privia to deliver care as part of a value-based care arrangement through a provider of primary care or specialty services as of the end of a particular period.(3)Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups.(j)Any slight variations in totals are due to rounding.

Non-GAAP Financial Measures (5)(k)

  For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in thousands)  2026   2025   2026   2025          Care Margin $132,146  $115,161  $260,876  $220,449 Platform Contribution $68,989  $57,466  $136,022  $109,199 Platform Contribution Margin  52.2%  49.9%  52.1%  49.5%Adjusted EBITDA $37,429  $28,992  $74,120  $55,907 Adjusted EBITDA Margin  28.3%  25.2%  28.4%  25.4%         (5)In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. Each are defined as follows:
  • Care Margin is Gross Profit excluding amortization of intangible assets.
  • Platform Contribution is Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform.
  • Platform Contribution margin is Platform Contribution divided by Care Margin.
  • Adjusted EBITDA is net income before interest income, net, provision for income taxes, net income attributable to non-controlling interests, depreciation and amortization, stock-based compensation, employer taxes on equity vesting/exercises, severance charges, contingent and deferred consideration, and other non-recurring expenses.
  • Adjusted EBITDA Margin is Adjusted EBITDA divided by Care Margin.
(k)Any slight variations in totals are due to rounding.

Reconciliation of Gross Profit to Care Margin(l)

  For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in thousands)  2026   2025   2026   2025 Revenue $        632,630  $        521,153  $        1,236,477  $        1,001,250 Provider expense          (500,484)          (405,992)          (975,601)          (780,801)Amortization of intangible assets          (3,211)          (2,396)          (6,346)          (4,069)Gross Profit $        128,935  $        112,765  $        254,530  $        216,380 Amortization of intangibles assets          3,211           2,396           6,346           4,069 Care Margin $        132,146  $        115,161  $        260,876  $        220,449 (l) Any slight variations in totals are due to rounding.

Reconciliation of Gross Profit to Platform Contribution(m)

  For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in thousands)  2026   2025   2026   2025 Revenue $        632,630  $        521,153  $        1,236,477  $        1,001,250 Provider expense          (500,484)          (405,992)          (975,601)          (780,801)Amortization of intangibles assets          (3,211)          (2,396)          (6,346)          (4,069)Gross Profit $        128,935  $        112,765  $        254,530  $        216,380 Amortization of intangibles assets          3,211           2,396           6,346           4,069 Cost of platform          (69,357)          (64,918)          (137,777)          (124,444)Stock-based compensation(6)          6,200           7,223           12,923           13,194 Platform Contribution $        68,989  $        57,466  $        136,022  $        109,199 (m) Any slight variations in totals are due to rounding.(6) Amount represents stock-based compensation expense included in Cost of platform.

Reconciliation of Net Income to Adjusted EBITDA(n)

  For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in thousands)  2026   2025   2026   2025 Net income $        9,048  $        2,687  $        12,112  $        6,907 Net income attributable to non-controlling interests          686           601           1,332           2,427 Provision for income taxes          7,017           2,456           12,617           4,559 Interest income, net          (1,668)          (2,408)          (3,556)          (5,339)Depreciation and amortization          3,356           2,583           6,637           4,484 Stock-based compensation          19,396           18,849           41,317           36,639 Other income          (3,310)          —           (3,310)          — Other expenses(7)          2,904           4,224           6,971           6,230 Adjusted EBITDA $        37,429  $        28,992  $        74,120  $        55,907          (n) Any slight variations in totals are due to rounding.(7) Other expenses include employer taxes on equity vesting/exercises, severance, contingent and deferred consideration, and other non-recurring expenses.

Reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share(o)

 For the Three Months Ended June 30, For the Six Months Ended June 30,(unaudited; $ in thousands) 2026  2025 (10)  2026  2025 (10)Net income$        9,048  $        2,687  $        12,112  $        6,907 Stock-based compensation         19,396           18,849           41,317           36,639 Intangible amortization expense         3,211           2,396           6,346           4,069 Other expenses(8)         2,904           4,224           6,971           6,230 Other income         (3,310)          —           (3,310)          — Tax effect of adjustments(9)         (5,994)          (6,877)          (13,857)          (12,673)Adjusted net income$        25,255  $        21,279  $        49,579  $        41,172 Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic$        0.20  $        0.17  $        0.40  $        0.34 Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted$        0.19  $        0.17  $        0.38  $        0.32 Weighted average common shares outstanding – basic         126,121,426           122,132,245           125,142,415           121,370,949 Weighted average common shares outstanding – diluted         131,827,233           128,447,069           131,355,421           128,149,252 (o) Any slight variations in totals due to rounding.(8) Other expenses include employer taxes on equity vesting/exercises, severance, contingent and deferred consideration, and other non-recurring expenses.(9) The Company uses a statutory blended tax rate of 27% on the adjustments between Net Income and Adjusted Net Income.(10) Updated to conform with current year presentation.



Risks

  • Highly regulated healthcare industry with risk of non-compliance affecting operations and financial results.
  • Dependence on maintaining favorable reimbursement rates and contracts with government and private payers amid changing payment landscapes.
  • Operational risks related to technology implementation, competition, and expansion into new geographic markets may impact future performance.

More from Press Releases

Safe Harbor's Cannabis-Focused 401(k) Plan Gains Early Adoption as Canopy HR Names It the Recommended Retirement Solution for its Clients Aug 6, 2026 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update Aug 6, 2026 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 6, 2026 Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Aug 6, 2026 Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Aug 6, 2026